Fda grants orphan designation for lipella's lp-310 drug candidate for oral graft-versus-host disease

Lipella pharmaceuticals' lp-310 clinical stage asset is formulated for delivering active agents to the oral cavity for diseases of the mouth including oral lichen planus and oral graft-versus-host disease pittsburgh , nov. 10, 2023 /prnewswire/ -- lipella pharmaceuticals inc. (nasdaq: lipo), a clinical stage pharmaceutical company addressing serious diseases with significant unmet need based in pittsburgh, pa, announced today that it has been granted "orphan drug designation" from the u.s. food and drug administration (fda) for its drug candidate, lp-310, which has been designed for the treatment of oral graft-versus-host disease (gvhd).  fda grants orphan designation for lipella's lp-310 drug candidate for oral graft-versus-host disease lp-310 is lipella's clinical stage pipeline asset intended to be indicated for inflammatory diseases of the oral cavity, including oral lichen planus and oral gvhd.
LIPO Ratings Summary
LIPO Quant Ranking